<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">problendo</journal-id><journal-title-group><journal-title xml:lang="ru">Проблемы Эндокринологии</journal-title><trans-title-group xml:lang="en"><trans-title>Problems of Endocrinology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0375-9660</issn><issn pub-type="epub">2308-1430</issn><publisher><publisher-name>Endocrinology Research Centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/probl13606</article-id><article-id custom-type="elpub" pub-id-type="custom">problendo-13606</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Детская эндокринология</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Pediatric Endocrinology</subject></subj-group></article-categories><title-group><article-title>Влияние пульс-терапии метилпреднизолоном на показатели углеводного обмена  у детей с хроническими аутоиммунными и аутовоспалительными заболеваниями</article-title><trans-title-group xml:lang="en"><trans-title>The effects of methylprednisolone pulse therapy on glucose metabolism parameters in children with autoimmune and autoinflammatory diseases</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5689-0194</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Витебская</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Vitebskaya</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Витебская Алиса Витальевна, к.м.н., доцент</p><p>119435, Москва, ул. Большая Пироговская, д. 19, стр. 2</p></bio><bio xml:lang="en"><p>Alisa V. Vitebskaya, MD, PhD, Associate Professor</p><p>19-2 B.Pirogovskaya street, 119435 Moscow</p></bio><email xlink:type="simple">dr.vitebskaya@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0701-5956</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Подзолкова</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Podzolkova</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Подзолкова Вера Алексеевна, к.м.н.</p><p>Москва</p></bio><bio xml:lang="en"><p>Vera A. Podzolkova, MD, PhD, Assistant Professor</p><p>Moscow</p></bio><email xlink:type="simple">v.a.podzolkova@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>I.M. Sechenov First Moscow State Medical University (Sechenov University)</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>08</day><month>09</month><year>2026</year></pub-date><volume>72</volume><issue>4</issue><fpage>63</fpage><lpage>69</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Витебская А.В., Подзолкова В.А., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Витебская А.В., Подзолкова В.А.</copyright-holder><copyright-holder xml:lang="en">Vitebskaya A.V., Podzolkova V.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.probl-endojournals.ru/jour/article/view/13606">https://www.probl-endojournals.ru/jour/article/view/13606</self-uri><abstract><sec><title>ОБОСНОВАНИЕ</title><p>ОБОСНОВАНИЕ. Применение высоких доз глюкокортикостероидов (ГКС) может приводить к развитию гипергликемии. Пульс-терапия (ПТ) ГКС обладает меньшими побочными эффектами по сравнению с длительным пероральным приемом ГКС у взрослых пациентов. Контроль гликемии на фоне ПТ ГКС в детском возрасте малоизучен.</p></sec><sec><title>ЦЕЛЬ</title><p>ЦЕЛЬ. Изучить краткосрочные и долгосрочные эффекты ПТ метилпреднизолоном на показатели углеводного обмена детей с хроническими аутоиммунными и аутовоспалительными заболеваниями</p></sec><sec><title>МАТЕРИАЛЫ И МЕТОДЫ</title><p>МАТЕРИАЛЫ И МЕТОДЫ. Проанализированы показатели углеводного обмена 15 пациентов (13 девочек, 2 мальчика) до, на фоне и после ПТ метилпреднизолоном (3 введения; 0 ч, 24 ч, 48 ч; суммарная доза 27,0 (23,0; 31,6) мг/кг). Наблюдение продолжалось от 0,2 до 6,3 лет.</p></sec><sec><title>РЕЗУЛЬТАТЫ</title><p>РЕЗУЛЬТАТЫ. Во время ПТ уровень гликемии превышал нормальные значения у всех пациентов через 4-10 ч после начала ПТ, достигая пика через 7 ч – 10,8 (9,9; 11,8) ммоль/л. Пики гликемии через 7 ч после второго и третьего введения были статистически значимо ниже по сравнению с первым днем – 9,1 (8,2; 10,7) ммоль/л (p&lt;0,05) и 8,9 (7,4; 9,2) ммоль/л (p&lt;0,01) соответственно. Через 24 ч после каждого введения ГКС отмечалась тенденция к нормализации гликемии. Значения гликемии через 72 ч не коррелировали с возрастом, SDS ИМТ, дозой метилпреднизолона и пиковыми значениями гликемии в ходе ПТ. Статистически значимых различий между показателями гликемии пациентов, впервые перенесших ПТ, и пациентов, имевших в прошлом опыт ПТ, выявлено не было.</p><p>Наблюдение в течение 2,7 (0,5; 4,6) лет не выявило отсроченных осложнений.</p></sec><sec><title>ЗАКЛЮЧЕНИЕ</title><p>ЗАКЛЮЧЕНИЕ. ПТ ГКС у детей приводила к краткосрочной ГКС-индуцированной гипергликемии. Максимальные значения гликемии отмечались через 7 ч после каждого введения ГКС; после повторных введений ГКС подъем гликемии был менее выражен, чем после первого введения. Спонтанная нормализация гликемии отмечалась через 24 часа после введения метилпреднизолона. Мы не выявили каких-либо отсроченных нарушений углеводного обмена.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>BACKGROUND</title><p>BACKGROUND: The use of glucocorticosteroids (GCS) in high doses can lead to hyperglycemia. GCS pulse therapy (PT) cause fewer side effects compared to long-term oral administration of GCS in adult patients. Glycemic control in children while GCS PT is not well studied.</p></sec><sec><title>AIM</title><p>AIM: To study short- and long-term effects of methylprednisolone pulse therapy on carbohydrate metabolism parameters in children with autoimmune and autoinflammatory diseases</p></sec><sec><title>MATERIALS AND METHODS</title><p>MATERIALS AND METHODS: We analyzed carbohydrate metabolism parameters of patients before, during, and after PT with methylprednisolone (3 infusions; 0 h, 24 h, 48 h; total dose 27.0 (23.0; 31.6) mg/kg). Observation lasted for 0.2–6.3 years.</p></sec><sec><title>RESULTS</title><p>RESULTS: We analyzed data from 15 patients (13 girls, 2 boys). During PT, the glycemia level exceeded normal rages in all patients in 4-10 hours after the start of PT, reaching a peak in 7 h – 10.8 (9.9; 11.8) mmol/l. Glycemia peaks 7 h after the second and the third infusions were significantly lower compared to the first day – 9.1 (8.2; 10.7) mmol/l (p&lt;0.05) and 8.9 (7.4; 9.2) mmol/l (p&lt;0.01), correspondently. A tendency toward normalization of glycemia was noted in 24 h after each administration of GCS. Glycemic values in 72 h did not correlate with age, SDS BMI, methylprednisolone dose, and peak glycemic values during PT. There were no significant differences between the glycemic indices of patients undergoing PT for the first time and those who already had experience of PT. Observation for 2.7 (0.5; 4.6) years did not reveal any delayed complications.</p></sec><sec><title>CONCLUSION</title><p>CONCLUSION: GCS PT in children resulted in short-term GCS-induced hyperglycemia. Peak glycemia values were observed in 7 hours after each GCS infusion; the rises of glycemia after repeated infusions were lower than after the first one. Spontaneous glycemia normalization was observed in 24 hours after methylprednisolone administration. We did not reveal any delayed disorders of carbohydrate metabolism.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>пульс-терапия</kwd><kwd>глюкокортикоиды</kwd><kwd>глюкоза крови</kwd><kwd>катамнез</kwd></kwd-group><kwd-group xml:lang="en"><kwd>pulse therapy</kwd><kwd>glucocorticoids</kwd><kwd>blood glucose</kwd><kwd>follow-up</kwd></kwd-group></article-meta></front><back><ref-list><ref id="cit1"><mixed-citation publication-type="commun" publication-format="web"><name><surname>Nakamura</surname> <given-names>H</given-names></name>, <name><surname>Fujieda</surname> <given-names>Y</given-names></name>, <name><surname>Nakamura</surname> <given-names>A</given-names></name>, <name><surname>Atsumi</surname> <given-names>T.</given-names></name> <article-title>How should rheumatologists manage glucocorticoid-induced hyperglycemia?</article-title> <source>Mod Rheumatol</source>. <year>2021</year>;<issue>31(3)</issue>:<fpage>519</fpage>–<lpage>28</lpage></mixed-citation></ref><ref id="cit2"><element-citation><name><surname>Pan</surname> <given-names>Lu</given-names> </name> <name><surname>Liu</surname> <given-names>Jinxiang</given-names> </name> <name><surname>Liu</surname> <given-names>Congcong</given-names> </name> <name><surname>Guo</surname> <given-names>Lishuang</given-names> </name> <name><surname>Yang</surname> <given-names>Sirui</given-names> </name> <article-title>Intermittent pulses of methylprednisolone with low-dose prednisone attenuate lupus symptoms in B6.MRL-Faslpr/J mice with fewer glucocorticoid side effects</article-title> <source>Biomedicine &amp; Pharmacotherapy</source> <year>2024</year> <month>07</month> <fpage>117138</fpage> <volume>177</volume> <object-id pub-id-type="doi" specific-use="metadata">10.1016/j.biopha.2024.117138</object-id></element-citation></ref><ref id="cit3"><element-citation><name><surname>Pofi</surname> <given-names>Riccardo</given-names> </name> <name><surname>Caratti</surname> <given-names>Giorgio</given-names> </name> <name><surname>Ray</surname> <given-names>David W</given-names> </name> <name><surname>Tomlinson</surname> <given-names>Jeremy W</given-names> </name> <article-title>Treating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the Bad ?</article-title> <source>Endocrine Reviews</source> <year>2023</year> <month>05</month> <fpage>975</fpage> <lpage>1011</lpage> <volume>44</volume> <issue>6</issue> <object-id pub-id-type="doi" specific-use="metadata">10.1210/endrev/bnad016</object-id></element-citation></ref><ref id="cit4"><mixed-citation publication-type="commun" publication-format="web"><name><surname>Ikeura</surname> <given-names>T</given-names></name>, <name><surname>Tomiyama</surname> <given-names>T</given-names></name>, <name><surname>Takaori</surname> <given-names>A</given-names></name>, <name><surname>Ito</surname> <given-names>T</given-names></name>, <name><surname>Nakamaru</surname> <given-names>K</given-names></name>, <name><surname>Masuda</surname> <given-names>M</given-names></name>, et al. <article-title>Long-term Outcomes after Steroid Pulse Therapy in Patients with Type 1 Autoimmune Pancreatitis</article-title>. <source>Intern Med Tokyo Jpn</source>. <year>2023</year>;<issue>62(20)</issue>:<fpage>2931</fpage>–<lpage>40</lpage></mixed-citation></ref><ref id="cit5"><element-citation><name><surname>Ali</surname> <given-names>Zulfiqar</given-names> </name> <name><surname>Shah</surname> <given-names>MohammadAkbar</given-names> </name> <name><surname>Mir</surname> <given-names>ShahidAhmad</given-names> </name> <name><surname>Hassan</surname> <given-names>Nelofar</given-names> </name> <name><surname>Masoodi</surname> <given-names>ShariqRashid</given-names> </name> <article-title>Effects of single dose of dexamethasone on perioperative blood glucose levels in patients undergoing surgery for supratentorial tumors – An observational study</article-title> <source>Anesthesia: Essays and Researches</source> <year>2020</year> <month>06</month> <fpage>56</fpage> <volume>14</volume> <issue>1</issue> <object-id pub-id-type="doi" specific-use="metadata">10.4103/aer.aer_21_20</object-id></element-citation></ref><ref id="cit6"><mixed-citation publication-type="commun" publication-format="web"><name><surname>van der Goes</surname> <given-names>MC</given-names></name>, <name><surname>Jacobs</surname> <given-names>JW</given-names></name>, <name><surname>Bijlsma</surname> <given-names>JW.</given-names></name> <article-title>Toward safer treatment with glucocorticoids: via patient and rheumatologist perspectives to recommendations on monitoring for adverse events</article-title>. <source>Clin Exp Rheumatol</source>. <year>2011</year>;<issue>29(5 Suppl 68)</issue>:<fpage>S116</fpage>-<lpage>20</lpage></mixed-citation></ref><ref id="cit7"><element-citation><name><surname>Bridgewater</surname> <given-names>Susan</given-names> </name> <name><surname>Shepherd</surname> <given-names>Michael A</given-names> </name> <name><surname>Dawson</surname> <given-names>Jill</given-names> </name> <name><surname>Richards</surname> <given-names>Pamela</given-names> </name> <name><surname>Silverthorne</surname> <given-names>Christine</given-names> </name> <name><surname>Ndosi</surname> <given-names>Mwidimi</given-names> </name> <name><surname>Almeida</surname> <given-names>Celia</given-names> </name> <name><surname>Black</surname> <given-names>Rachel J</given-names> </name> <name><surname>Cheah</surname> <given-names>Jonathan T L</given-names> </name> <name><surname>Dures</surname> <given-names>Emma</given-names> </name> <name><surname>Ghosh</surname> <given-names>Nilasha</given-names> </name> <name><surname>Hoon</surname> <given-names>Elizabeth A</given-names> </name> <name><surname>Lyne</surname> <given-names>Suellen</given-names> </name> <name><surname>Navarro-Millan</surname> <given-names>Iris</given-names> </name> <name><surname>Pearce-Fisher</surname> <given-names>Diyu</given-names> </name> <name><surname>Ruediger</surname> <given-names>Carlee</given-names> </name> <name><surname>Tieu</surname> <given-names>Joanna</given-names> </name> <name><surname>Yip</surname> <given-names>Kevin</given-names> </name> <name><surname>Mackie</surname> <given-names>Sarah L</given-names> </name> <name><surname>Goodman</surname> <given-names>Susan</given-names> </name> <name><surname>Hill</surname> <given-names>Catherine</given-names> </name> <name><surname>Robson</surname> <given-names>Joanna C</given-names> </name> <article-title>Measuring the impact of steroid therapy on health-related quality of life in patients with rheumatic diseases: international development of a glucocorticoid treatment–specific patient-reported outcome measure</article-title> <source>Rheumatology</source> <year>2023</year> <month>02</month> <fpage>3565</fpage> <lpage>3575</lpage> <volume>62</volume> <issue>11</issue> <object-id pub-id-type="doi" specific-use="metadata">10.1093/rheumatology/kead081</object-id></element-citation></ref><ref id="cit8"><mixed-citation publication-type="commun" publication-format="web"><name><surname>Li</surname> <given-names>JX</given-names></name>, <name><surname>Cummins</surname> <given-names>CL.</given-names></name> <article-title>Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions</article-title>. <source>Nat Rev Endocrinol</source>. <year>2022</year>;<issue>18(9)</issue>:<fpage>540</fpage>–<lpage>57</lpage></mixed-citation></ref><ref id="cit9"><mixed-citation publication-type="commun" publication-format="web"><name><surname>Véber</surname> <given-names>O</given-names></name>, <name><surname>Wilde</surname> <given-names>A</given-names></name>, <name><surname>Demeter</surname> <given-names>J</given-names></name>, <name><surname>Tamás</surname> <given-names>G</given-names></name>, <name><surname>Mucsi</surname> <given-names>I</given-names></name>, <name><surname>Tabák</surname> <given-names>AG.</given-names></name> <article-title>The effect of steroid pulse therapy on carbohydrate metabolism in multiple myeloma patients: a randomized crossover observational clinical study</article-title>.<source> J Endocrinol Invest.</source> <year>2014</year>;<issue>37(4)</issue>:<fpage>345</fpage>–<lpage>51</lpage></mixed-citation></ref><ref id="cit10"><mixed-citation publication-type="commun" publication-format="web"><name><surname>Tanaka</surname> <given-names>K</given-names></name>, <name><surname>Okada</surname> <given-names>Y</given-names></name>, <name><surname>Mori</surname> <given-names>H</given-names></name>, <name><surname>Torimoto</surname> <given-names>K</given-names></name>, <name><surname>Arao</surname> <given-names>T</given-names></name>, <name><surname>Tanaka</surname> <given-names>Y.</given-names></name> <article-title>The Effects of Mitiglinide and Repaglinide on Postprandial Hyperglycemia in Patients Undergoing Methylprednisolone Pulse Therapy</article-title>. <source>Intern Med</source>. <year>2018</year>;<issue>57(1)</issue>:<fpage>65</fpage>–<lpage>70</lpage></mixed-citation></ref><ref id="cit11"><element-citation><name><surname>Bhardwaj</surname> <given-names>Umang</given-names> </name> <name><surname>Bagri</surname> <given-names>Narendra K</given-names> </name> <name><surname>Lodha</surname> <given-names>Rakesh</given-names> </name> <name><surname>Kabra</surname> <given-names>Sushil K</given-names> </name> <name><surname>Velpandian</surname> <given-names>Thirumurthy</given-names> </name> <name><surname>Pandey</surname> <given-names>Ravindra M</given-names> </name> <article-title>Efficacy of pulse dexamethasone in non-systemic juvenile idiopathic arthritis: a double-blind randomized controlled trial</article-title> <source>Rheumatology</source> <year>2021</year> <month>12</month> <fpage>3370</fpage> <lpage>3377</lpage> <volume>61</volume> <issue>8</issue> <object-id pub-id-type="doi" specific-use="metadata">10.1093/rheumatology/keab914</object-id></element-citation></ref><ref id="cit12"><element-citation><name><surname>Toyoshima</surname> <given-names>Marcos Tadashi Kakitani</given-names> </name> <name><surname>Cukier</surname> <given-names>Priscilla</given-names> </name> <name><surname>Souza</surname> <given-names>Alexandre Barbosa Câmara de</given-names> </name> <name><surname>Pereira</surname> <given-names>Juliana</given-names> </name> <name><surname>Hoff</surname> <given-names>Ana Oliveira</given-names> </name> <name><surname>Nery</surname> <given-names>Marcia</given-names> </name> <article-title>Effects of glucocorticoids on interstitial glucose concentrations in individuals with hematologic cancer and without known diagnosis of diabetes: a pilot study</article-title> <source>einstein (São Paulo)</source> <year>2022</year> <month>07</month> <volume>20</volume> <object-id pub-id-type="doi" specific-use="metadata">10.31744/einstein_journal/2022ao8031</object-id></element-citation></ref><ref id="cit13"><mixed-citation publication-type="commun" publication-format="web"><name><surname>Zhou</surname> <given-names>Y</given-names></name>, <name><surname>Zhao</surname> <given-names>Y</given-names></name>, <name><surname>Yuan</surname> <given-names>T</given-names></name>, <name><surname>Jiang</surname> <given-names>N</given-names></name>, <name><surname>Dong</surname> <given-names>Y</given-names></name>, <name><surname>Yang</surname> <given-names>Y</given-names></name>, et al. <article-title>High dose glucocorticoid treatment does not induce hyperglycemia in young patients with autoimmune diseases by CGMS</article-title>. <source>Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol</source>. <year>2018</year>;<issue>24(1)</issue>:<fpage>60</fpage>–<lpage>8</lpage></mixed-citation></ref><ref id="cit14"><mixed-citation publication-type="commun" publication-format="web"><name><surname>Lyall</surname> <given-names>MJ</given-names></name>, <name><surname>Thethy</surname> <given-names>I</given-names></name>, <name><surname>Steven</surname> <given-names>L</given-names></name>, <name><surname>MacKean</surname> <given-names>M</given-names></name>, <name><surname>Nussey</surname> <given-names>F</given-names></name>, <name><surname>Sakala</surname> <given-names>M</given-names></name>, et al. <article-title>Diurnal profile of interstitial glucose following dexamethasone prophylaxis for chemotherapy treatment of gynaecological cancer</article-title>. <source>Diabet Med J Br Diabet Assoc.</source> <year>2018</year>;<issue>35(11)</issue>:<fpage>1508</fpage>–<lpage>14</lpage></mixed-citation></ref><ref id="cit15"><element-citation><name><surname>Vitebskaya</surname> <given-names>Alisa V.</given-names> </name> <name><surname>Popovich</surname> <given-names>Anastaiya V.</given-names> </name> <name><surname>Afonina</surname> <given-names>Elena Y.</given-names> </name> <name><surname>Kostina</surname> <given-names>Yuliya O.</given-names> </name> <name><surname>Aleksanyan</surname> <given-names>Karina V.</given-names> </name> <name><surname>Grammatopulo</surname> <given-names>Mariya I.</given-names> </name> <name><surname>Yablokova</surname> <given-names>Ekaterina A.</given-names> </name> <name><surname>Shpitonkova</surname> <given-names>Olga V.</given-names> </name> <article-title>Characteristics of insulin therapy of diabetes mellitus type 1 in children and adolescents receiving glucocorticoids</article-title> <source>Diabetes mellitus</source> <year>2019</year> <month>06</month> <fpage>263</fpage> <lpage>273</lpage> <volume>22</volume> <issue>3</issue> <object-id pub-id-type="doi" specific-use="metadata">10.14341/dm10042</object-id></element-citation></ref><ref id="cit16"><element-citation><name><surname>He</surname> <given-names>Xingxing</given-names> </name> <name><surname>Duan</surname> <given-names>Guangchen</given-names> </name> <name><surname>Lu</surname> <given-names>Jingyi</given-names> </name> <name><surname>Wang</surname> <given-names>Yaxin</given-names> </name> <name><surname>Cai</surname> <given-names>Jinghao</given-names> </name> <name><surname>Tong</surname> <given-names>Yiqing</given-names> </name> <name><surname>Wu</surname> <given-names>Wei</given-names> </name> <name><surname>Ma</surname> <given-names>Xiaojing</given-names> </name> <name><surname>Feng</surname> <given-names>Qiming</given-names> </name> <name><surname>Zhou</surname> <given-names>Jian</given-names> </name> <article-title>Continuous glucose monitoring profile in COVID-19 patients with and without diabetes receiving methylprednisolone</article-title> <source>Endocrine</source> <year>2024</year> <month>05</month> <fpage>556</fpage> <lpage>563</lpage> <volume>86</volume> <issue>2</issue> <object-id pub-id-type="doi" specific-use="metadata">10.1007/s12020-024-03841-0</object-id></element-citation></ref><ref id="cit17"><mixed-citation publication-type="commun" publication-format="web"><name><surname>Merkofer</surname> <given-names>F</given-names></name>, <name><surname>Struja</surname> <given-names>T</given-names></name>, <name><surname>Delfs</surname> <given-names>N</given-names></name>, <name><surname>Spagnuolo</surname> <given-names>CC</given-names></name>, <name><surname>Hafner</surname> <given-names>JF</given-names></name>, <name><surname>Kupferschmid</surname> <given-names>K</given-names></name>, et al. <article-title>Glucose control after glucocorticoid administration in hospitalized patients - a retrospective analysis</article-title>. <source>BMC Endocr Disord</source>. <year>2022</year> <month>Jan</month> 5;<issue>22(1)</issue>:8</mixed-citation></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
